Respiratory Impact of LA Volume After IS Block
Arthroscopic Surgery of the Shoulder, Extrafascial Interscalene Plexus Brachial Block

About this trial
This is an interventional treatment trial for Arthroscopic Surgery of the Shoulder
Eligibility Criteria
Inclusion Criteria:
- arthroscopic surgery of the shoulder
- ASA class 1 to 3
- age more than 18 years old
Exclusion Criteria:
- patient refusal or inability to understand and/or sign the inform consent
- contraindication for perineural block (allergy to local anesthetics, infection of puncture site, major coagulopathy, sensitive or motor deficiency on the operative side arm
- chronic alcool abuse
- opioid drug abuse or under substitution treatment
- patients known for allergies to paracetamol, non steroidal anti inflammatory drugs, dexamethasone, sulfate magnesium, ondansetron, droperidol, and omeprazole;
- patients under chronic corticotherapy
- patients known for malignant hyperthermia;
- patients with chronic kidney failure (Glomerular Filtration Rate < 20 ml/min)
- patients with severe pulmonary disease
- patients with history of neck surgery or radiotherapy on the operative side;
- pregnancy
Sites / Locations
- CHUV (Centre Hospitalier Universitaire Vaudois)Recruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
10 ml single-shot injection
20 ml single-shot injection group
In the 10ml group, participants will have an interscalene brachial plexus with an extrafascial injection of 10 ml ropivacaine 0.75% at the level of C5-C6 nerves roots. Participants will also receive multimodal analgesia with injection of dexamethasone 8 mg iv, magnesium sulfate 40 mg kg^-1 iv, ketorolac 30 mg iv, and acetaminophen 1000 mg iv, according to the current practice in our institution.
In the 20ml group, participants will have an interscalene brachial plexus with an extrafascial injection of 20 ml ropivacaine 0.75% at the level of C5-C6 nerves roots. Participants will also receive multimodal analgesia with injection of dexamethasone 8 mg iv, magnesium sulfate 40 mg kg^-1 iv, ketorolac 30 mg iv, and acetaminophen 1000 mg iv, according to the current practice in our institution.